Gate Bio emerged from stealth with a $60M series A and a small molecule platform for selective gating of protein secretion

Gate Bioscience has raised $60 million to develop a new type of pill-based medicine — which it calls a molecular gate — that can go after the spectrum of malicious proteins.

The company last year raised a $60 million Series A round led by Versant Ventures and Andreessen Horowitz and including ARCH Venture Partners and GV.